Literature DB >> 27134116

2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Claudia Vergelli1, Igor A Schepetkin2, Giovanna Ciciani1, Agostino Cilibrizzi3, Letizia Crocetti1, Maria Paola Giovannoni4, Gabriella Guerrini1, Antonella Iacovone1, Liliya N Kirpotina2, Andrei I Khlebnikov5, Richard D Ye6, Mark T Quinn2.   

Abstract

N-Formyl peptide receptors (FPRs: FPR1, FPR2, and FPR3) are G protein-coupled receptors that play key roles in modulating immune cells. FPRs represent potentially important therapeutic targets for the development of drugs that could enhance endogenous anti-inflammation systems associated with various pathologies, thereby reducing the progression of inflammatory conditions. Previously, we identified 2-arylacetamide pyridazin-3(2H)-ones as FPR1- or FPR2-selective agonists, as well as a large number of FPR1/FPR2-dual agonists and several mixed-agonists for the three FPR isoforms. Here, we report a new series of 2-arylacetamido-4-aniline pyridazin-3(2H)-ones substituted in position 5 as a further development of these FPR agonists. Chemical manipulation presented in this work resulted in mixed FPR agonists 8a, 13a and 27b, which had EC50 values in nanomolar range. In particular, compound 8a showed a preference for FPR1 (EC50=45nM), while 13a and 27b showed a moderate preference for FPR2 (EC50=35 and 61nM, respectively). Thus, these compounds may represent valuable tools for studying FPR activation and signaling.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Agonist; Ca(2+) mobilization; Formyl peptide receptor (FPR); Neutrophil; Pyridazin-3(2H)-one

Year:  2016        PMID: 27134116      PMCID: PMC5055850          DOI: 10.1016/j.bmc.2016.04.019

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  34 in total

1.  FPR2/ALXR agonists and the resolution of inflammation.

Authors:  Olivier Corminboeuf; Xavier Leroy
Journal:  J Med Chem       Date:  2014-11-03       Impact factor: 7.446

Review 2.  Inflammatory resolution: new opportunities for drug discovery.

Authors:  Derek W Gilroy; Toby Lawrence; Mauro Perretti; Adriano G Rossi
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

Review 3.  Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists.

Authors:  Neil Dufton; Mauro Perretti
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

4.  Synthesis of five and six-membered heterocycles bearing an arylpiperazinylalkyl side chain as orally active antinociceptive agents.

Authors:  Claudia Vergelli; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Gabriella Guerrini; Antonella Iacovone; Maria Paola Giovannoni
Journal:  Bioorg Med Chem       Date:  2015-09-02       Impact factor: 3.641

Review 5.  Neutrophils and immunity: challenges and opportunities.

Authors:  Carl Nathan
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

6.  Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Ni Cheng; Richard D Ye; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2014-10-17       Impact factor: 5.858

7.  The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2.

Authors:  Matthew P Wood; Amy L Cole; Colleen R Eade; Li-Mei Chen; Karl X Chai; Alexander M Cole
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 8.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

9.  N(6)-[(hetero)aryl/(cyclo)alkyl-carbamoyl-methoxy-phenyl]-(2-chloro)-5'-N-ethylcarboxamido-adenosines: the first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor.

Authors:  Pier Giovanni Baraldi; Delia Preti; Mojgan Aghazadeh Tabrizi; Francesca Fruttarolo; Giulia Saponaro; Stefania Baraldi; Romeo Romagnoli; Allan R Moorman; Stefania Gessi; Katia Varani; Pier Andrea Borea
Journal:  Bioorg Med Chem       Date:  2007-02-02       Impact factor: 3.641

10.  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.

Authors:  Maria Paola Giovannoni; Igor A Schepetkin; Agostino Cilibrizzi; Letizia Crocetti; Andrei I Khlebnikov; Claes Dahlgren; Alessia Graziano; Vittorio Dal Piaz; Liliya N Kirpotina; Serena Zerbinati; Claudia Vergelli; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2013-04-08       Impact factor: 6.514

View more
  7 in total

1.  Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Richard D Ye; Mark T Quinn
Journal:  Drug Dev Res       Date:  2016-11-18       Impact factor: 4.360

2.  Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.

Authors:  Letizia Crocetti; Claudia Vergelli; Gabriella Guerrini; Niccolò Cantini; Liliya N Kirpotina; Igor A Schepetkin; Mark T Quinn; Carmen Parisio; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Maria Paola Giovannoni
Journal:  Bioorg Chem       Date:  2020-04-28       Impact factor: 5.275

3.  Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity.

Authors:  Niccolo Cantini; Igor A Schepetkin; Nadezhda V Danilenko; Andrei I Khlebnikov; Letizia Crocetti; Maria Paola Giovannoni; Liliya N Kirpotina; Mark T Quinn
Journal:  Molecules       Date:  2022-06-10       Impact factor: 4.927

4.  Pyridinone Derivatives as Interesting Formyl Peptide Receptor (FPR) Agonists for the Treatment of Rheumatoid Arthritis.

Authors:  Letizia Crocetti; Claudia Vergelli; Gabriella Guerrini; Maria Paola Giovannoni; Liliya N Kirpotina; Andrei I Khlebnikov; Carla Ghelardini; Lorenzo Di Cesare Mannelli; Elena Lucarini; Igor A Schepetkin; Mark T Quinn
Journal:  Molecules       Date:  2021-10-30       Impact factor: 4.411

5.  Exploration of nitrogen heterocycle scaffolds for the development of potent human neutrophil elastase inhibitors.

Authors:  Niccolò Cantini; Andrei I Khlebnikov; Letizia Crocetti; Igor A Schepetkin; Giuseppe Floresta; Gabriella Guerrini; Claudia Vergelli; Gianluca Bartolucci; Mark T Quinn; Maria Paola Giovannoni
Journal:  Bioorg Med Chem       Date:  2020-11-06       Impact factor: 3.641

6.  Correspondence: Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury.

Authors:  Agostino Cilibrizzi
Journal:  Nat Commun       Date:  2018-02-07       Impact factor: 14.919

7.  Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists.

Authors:  Claudia Vergelli; Andrei I Khlebnikov; Letizia Crocetti; Gabriella Guerrini; Niccolò Cantini; Liliya N Kirpotina; Igor A Schepetkin; Agostino Cilibrizzi; Mark T Quinn; Patrizia Rossi; Paola Paoli; Maria Paola Giovannoni
Journal:  Chem Biol Drug Des       Date:  2021-07-01       Impact factor: 2.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.